跳至主要内容
临床试验/NCT00296387
NCT00296387已完成3 期

Comparison of the Effects Noted in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With acUte Coronary Syndrome - CENTAURUS

AstraZeneca102 个研究点 分布在 6 个国家目标入组 1,160 人开始时间: 2006年1月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
AstraZeneca
入组人数
1,160
试验地点
102
主要终点
Percentage changes in ApoB/ApoA-I levels

研究概览

简要总结

The purpose of this study is to see if rosuvastatin compared to Atorvastatin is effective in treating ACS by decreasing the ApoB/ApoA-1 ratio and if starting statin within 24 h following the onset of the first symptoms is beneficial compared to placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Hospital admission for ACS with chest pain or discomfort occurring during rest or with minimal exertion,
  • Percutaneous coronary intervention (PCI) planned,
  • Evidence of coronary artery disease

排除标准

  • Hypersensitivity to statins
  • Any cholesterol lowering medication taken within 1 month prior V1
  • Sustained ST-segment elevation on ECG

结局指标

主要结局

Percentage changes in ApoB/ApoA-I levels

时间窗: from Day 0 to 3 months

次要结局

  • Percentage changes in LDL-C(from Day 0 to 1 month and 3 months)
  • Percentage changes in the hs-CRP and AUC of hs-CRP levels(from Day -6 to Day 0)
  • Percentage changes in ApoA-I(from Day 0 to 1 month)

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (102)

Loading locations...

相似试验